Lung Squamous Cell Carcinoma With Anaplastic Lymphoma Kinase Rearrangement and TP53 Co-mutation Treated Successfully with Ensartinib: A Case Report
暂无分享,去创建一个
[1] A. Jemal,et al. Cancer statistics, 2018 , 2018, CA: a cancer journal for clinicians.
[2] Yi-long Wu,et al. Clinical trials of tyrosine kinase inhibitors for lung cancer in China: a review , 2017, Journal of Hematology & Oncology.
[3] T. Nakajima,et al. ALK-rearranged lung squamous cell carcinoma responding to alectinib: a case report and review of the literature , 2017, BMC Cancer.
[4] G. Pinotti,et al. ALK-Rearranged Squamous Cell Carcinoma of the Lung Treated with Two Lines of ALK Inhibitors. , 2017, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.
[5] Matteo Canale,et al. Impact of TP53 Mutations on Outcome in EGFR-Mutated Patients Treated with First-Line Tyrosine Kinase Inhibitors , 2016, Clinical Cancer Research.
[6] A. Marusyk,et al. Collateral sensitivity networks reveal evolutionary instability and novel treatment strategies in ALK mutated non-small cell lung cancer , 2016, bioRxiv.
[7] Yoon-La Choi,et al. ALK, ROS1 and RET rearrangements in lung squamous cell carcinoma are very rare. , 2016, Lung cancer.
[8] Yiping Zhang,et al. Response to crizotinib in a squamous cell lung carcinoma patient harbouring echinoderm microtubule‐associated protein‐like 4‐anaplastic lymphoma translocation: A case report , 2015, Thoracic cancer.
[9] M. Studnicka,et al. First line crizotinib in anaplastic lymphoma kinase (ALK) rearranged squamous cell lung cancer. , 2015, Lung cancer.
[10] S. Shimizu,et al. A Case of Squamous Cell Carcinoma Harboring an EML4-ALK Rearrangement that Was Unsuccessfully Treated with the ALK Inhibitor Alectinib. , 2015, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.
[11] Quan Zhang,et al. ALK-rearranged squamous cell lung cancer: a case report. , 2015, International journal of clinical and experimental pathology.
[12] Hua-liang Xiao,et al. Extraordinary response to crizotinib in a woman with squamous cell lung cancer after two courses of failed chemotherapy , 2014, BMC Pulmonary Medicine.
[13] D. Costa,et al. Esophagitis: a novel adverse event of crizotinib in a patient with ALK-positive non-small-cell lung cancer. , 2013, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.
[14] M. Varella‐Garcia,et al. ALK Gene Rearrangements: A New Therapeutic Target in a Molecularly Defined Subset of Non-small Cell Lung Cancer , 2009, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.
[15] C. Castro,et al. Changing trends in the distribution of the histologic types of lung cancer: a review of 4,439 cases. , 2007, Annals of Diagnostic Pathology.